Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 11,264 Shares of Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 11,264 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $18.42, for a total value of $207,482.88. Following the sale, the director owned 325,795 shares in the company, valued at approximately $6,001,143.90. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Maplight Therapeutics Stock Down 1.5%

Maplight Therapeutics stock opened at $18.02 on Wednesday. The business’s fifty day moving average is $17.83. Maplight Therapeutics, Inc. has a fifty-two week low of $12.24 and a fifty-two week high of $21.55. The stock has a market capitalization of $817.57 million and a P/E ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Analyst Ratings Changes

A number of equities analysts have commented on MPLT shares. Jefferies Financial Group began coverage on Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $32.00 target price for the company. Morgan Stanley began coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued an “overweight” rating and a $34.00 target price on the stock. Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Leerink Partners initiated coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Maplight Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $31.00.

Hedge Funds Weigh In On Maplight Therapeutics

Several hedge funds have recently made changes to their positions in MPLT. Strs Ohio purchased a new stake in shares of Maplight Therapeutics during the fourth quarter valued at $53,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Maplight Therapeutics during the 4th quarter worth about $70,000. New York State Common Retirement Fund purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $93,000. MetLife Investment Management LLC acquired a new position in shares of Maplight Therapeutics in the fourth quarter worth about $172,000. Finally, Walleye Capital LLC purchased a new position in shares of Maplight Therapeutics in the fourth quarter worth approximately $205,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.